Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-54.85%||ROE||432.02%||ROI|
|Current Ratio||9.53||Quick Ratio||Long Term Debt/Equity||1.23||Debt Ratio||-0.77|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||5.41 M||Cash From Investing Activities||-50.01 M||Cash From Operating Activities||-23.15 M||Gross Profit|
|Net Profit||-27.39 M||Operating Profit||-22.8 M||Total Assets||194.83 M||Total Current Assets||182.28 M|
|Total Current Liabilities||19.13 M||Total Debt||200 M||Total Liabilities||219.57 M||Total Revenue|
|High 52 week||2.64||Low 52 week||0.08||Last close||0.09||Last change||-18.15%|
|RSI||16.15||Average true range||0.05||Beta||0.78||Volume||31.45 M|
|Simple moving average 20 days||-71.25%||Simple moving average 50 days||-86.2%||Simple moving average 200 days||-94.19%|
|Performance Week||-45.88%||Performance Month||-77.91%||Performance Quart||-94.94%||Performance Half||-95.8%|
|Performance Year||-95.67%||Performance Year-to-date||-96.12%||Volatility daily||21.8%||Volatility weekly||48.74%|
|Volatility monthly||99.88%||Volatility yearly||346.01%||Relative Volume||577.63%||Average Volume||8.71 M|
|New High||New Low|
2019-01-09 08:03:43 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2019-01-07 10:46:20 | [$$] Charlotte Russe Reassesses Its Future, Including Sale or Bankruptcy
2019-01-04 17:52:13 | [$$] Synergy Pharmaceuticals Wins Court Approval for Extended Sale Process
2019-01-04 10:10:00 | These 4 Healthcare Stocks Are Making Moves
2019-01-02 11:55:00 | These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang
2018-12-31 08:59:00 | 4 Pharma Stocks Gaining Speed on Monday 12/31/18
2018-12-28 13:33:17 | [$$] Firm Retention Summary: Synergy Pharmaceuticals Inc.
2018-12-21 10:45:00 | These 4 Pharma Stocks Could Test December Highs
2018-12-20 08:02:09 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-12-19 12:30:00 | These 4 Pharma Stocks Are Heating Up
2018-12-18 06:40:00 | 4 Stocks to Watch Pre-Market on Tuesday 12/18/2018
2018-12-17 13:30:00 | 4 Stocks Providing Investor Opportunity Right Now
2018-12-17 10:33:22 | [$$] Neiman Marcus Asks Court to Dismiss Lawsuit by Marble Ridge
2018-12-17 07:00:00 | Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada
2018-12-14 13:50:14 | [$$] Synergy Pharmaceuticals Kicks Off Path Toward Sale
2018-12-13 09:02:02 | Bausch BHC Bids for Assets of Synergy Pharmaceuticals
2018-12-12 13:21:16 | No Emoji Could Hide This Drugmaker’s Woes
2018-12-12 12:36:14 | Synergy Pharmaceuticals Bankruptcy: SGYP Stock Plummets on Filing
2018-12-12 10:40:33 | [$$] Former Pharma Highflier Appreciates Bathroom Humor
2018-12-12 09:36:07 | [$$] Bausch Health Agrees to Buy Synergy Pharmaceuticals for $200 Million
2018-12-06 08:02:23 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-24 08:03:52 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-13 08:25:00 | Recent Analysis Shows Brown Forman, CryoLife, Aspen Group, Taylor Devices, Synergy Pharmaceuticals, and Ramco-Gershenson Properties Trust Market Influences — Renewed Outlook, Key Drivers of Growth
2018-11-13 08:02:39 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-08 20:30:01 | Synergy Pharmaceuticals SGYP Reports Q3 Loss, Misses Revenue Estimates
2018-11-08 19:26:07 | Synergy Pharma: 3Q Earnings Snapshot
2018-11-08 17:00:00 | Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update
2018-11-02 10:49:24 | What We Can Learn From Synergy Pharmaceuticals' Disastrous News
2018-11-01 20:21:00 | Scary Markets, Frightening Stocks, and How to Keep From Panicking
2018-10-31 17:00:00 | Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman
2018-10-26 16:55:45 | Why Synergy Pharmaceuticals, Tesla, Tencent and More Are Trending
2018-10-26 10:45:26 | [$$] Investors Frown on Biotech Famed for Emojis
2018-10-26 10:45:00 | Why Synergy Pharmaceuticals Is Being Obliterated Today
2018-10-25 17:00:00 | Synergy Pharmaceuticals Provides Business Update
2018-10-08 08:00:00 | Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® plecanatide in Two Patient Populations at the American College of Gastroenterology ACG Annual Scientific Meeting
2018-10-03 09:41:01 | Is the Options Market Predicting a Spike in Synergy Pharmaceuticals SGYP Stock?
2018-09-15 08:04:01 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-09-11 09:12:00 | Here's Why Synergy Pharmaceuticals Rose 14.1% in August
2018-08-31 08:46:12 | Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals SGYP Stock?
2018-08-31 08:00:00 | Market Trends Toward New Normal in Sykes Enterprises, Carnival, Covenant Transportation Group, Synergy Pharmaceuticals, Regeneron Pharmaceuticals, and Minerals Technologies — Emerging Consolidated Expectations, Analyst Ratings
2018-08-23 08:07:06 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.